Comments on Glintborg et al.'s drug-drug interactions study (EJCP 2005; 61:675-681)

European Journal of Clinical Pharmacology

Volumn 62, Issue 2, 2006, Pages 159-

  Naunton, Mark ^a   Duyvendak, Michiel ^a,b   Peterson, Gregory M ^a,c   Brouwers, Jacobus R J B ^a,d  

^a Department of Pharmacotherapy and Pharmaceutical Care ^*  (Netherlands)

^b Tjongerschans Hospital   (Netherlands)

^c UNIVERSITY OF TASMANIA   (Australia)

^d UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; POTASSIUM; SPIRONOLACTONE;

DRUG ANTAGONISM; DRUG INHIBITION; DRUG SCREENING; GENERAL PRACTITIONER; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HYPERKALEMIA; LETTER; MEDICAL PRACTICE; MEDICAL RECORD; PRIORITY JOURNAL; PUBLICATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; DRUG INTERACTIONS; HOSPITALIZATION; HUMANS; MIDDLE AGED; PHARMACEUTICAL PREPARATIONS;

EID: 33645419766     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-005-0074-y     Document Type: Letter

References (5)

1. Glintborg B, Andersen SE, Dalhoff K (2005) Drug-drug interactions among recently hospitalised patients-frequent but mostly clinically insignificant. Eur J Clin Pharmacol 61:675-681
2. Kucukarslan SN, Peters M, Mlynarek M, Nafziger DA (2003) Pharmacists on rounding teams reduce preventable adverse drug events in hospital general medicine units. Arch Intern Med 163(17):2014-2018
3. Shah KB, Rao K, Sawyer R, Gottlieb SS (2005) The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure. J Am Coll Cardiol 46(5):845-849
4. Juurlink DN, Mamdani MM, Lee DS, et al (2004) Rates of hyperkalaemia after publication of the randomized Aldactone evaluation study. N Eng J Med 351(6):543-551
5. Juurlink DN, Mamdani M, Kopp A et al (2003) Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA. Apr 2;289(13):1652-1658